How common is vomiting with ivosidenib combined with azacitidine for newly diagnosed acute myeloid leukaemia?

With ivosidenib plus azacitidine for newly diagnosed acute myeloid leukaemia, vomiting (including retching) was very common, reported in 40% of 72 treated patients; frequencies reflect all-cause adverse events, some potentially due to disease, other medicines or unrelated causes rather than ivosidenib.